Stocks / NASDAQ / Genocea Biosciences, Inc.

Genocea Biosciences, Inc.

Our Opinion

Genocea Biosciences, Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical analysis and clinical research.

Supporting Evidence:

The company stated in the following document that they conduct pre-clinical trials of their drugs on animals.

“ATLAS is fast, too.  Genocea took four programs in three diseases from project initiation to animal proof-of-concept, and two vaccines into the clinic, all in seven years. This compares favorably against the traditional 10-to-12-year pace of discovery in the vaccine space” (Page 2) Read the full document.

Company Description

Genocea Biosciences is a biopharmaceutical company developing T cell-directed vaccines and immunotherapies to treat infectious diseases and cancer. The company uses its proprietary ATLAS™ antigen identification platform to build a pipeline of immunotherapies that currently includes GEN-003, an immunotherapy for genital herpes, and GEN-009, its first neoantigen cancer vaccine, for which an Investigational New Drug application filing is expected by the end of 2017. Genocea Biosciences was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA. [Source: MarketWatch]

Company Website: